Welcome to our dedicated page for Alkermes Plc SEC filings (Ticker: ALKS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alkermes plc (ALKS) SEC filings page on Stock Titan brings together the companys regulatory disclosures from the U.S. Securities and Exchange Commission, offering structured access to its Forms 8-K and other key documents. Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline that includes alixorexton, an investigational orexin 2 receptor agonist for narcolepsy and idiopathic hypersomnia.
Through its current reports on Form 8-K, Alkermes provides official details on material events. These include financial result announcements, where the company reports quarterly revenues, net income, EBITDA and adjusted EBITDA, along with updates to its annual financial expectations. Such filings often include reconciliations of non-GAAP measures like EBITDA and adjusted EBITDA and discuss revenue contributions from proprietary products and manufacturing and royalty arrangements.
Alkermes also uses Form 8-K to disclose clinical and regulatory milestones, such as positive topline results from phase 2 studies of alixorexton in narcolepsy type 1 and type 2, and to furnish related investor presentations. These documents help readers understand the design, endpoints and topline outcomes of the Vibrance studies and the companys plans for further development.
Another important category of filings relates to transaction agreements and financing. Alkermes has filed a transaction agreement and an amendment describing the terms under which it proposes to acquire Avadel Pharmaceuticals plc, including cash consideration per share and a non-transferable contingent value right linked to a potential regulatory milestone for LUMRYZ. The company has also filed an amended and restated bridge term loan credit agreement, outlining a senior secured bridge term loan facility intended to support financing of the proposed acquisition, along with associated covenants and security arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly identify items such as earnings updates, clinical trial disclosures, transaction terms and new financing commitments. Real-time updates from EDGAR allow investors to see new ALKS filings as they appear, while structured access to exhibits makes it easier to review detailed agreements, credit facilities and presentation materials.
For those tracking insider and governance information, Alkermes broader SEC reporting framework also encompasses ownership and compensation disclosures in its periodic and proxy filings, which can be accessed alongside 8-Ks. Together, these documents form a detailed record of Alkermes financial condition, strategic transactions, development progress and capital structure.
Alkermes PLC ownership disclosure: Vanguard Portfolio Management reports beneficial ownership of 9,647,056 shares of Alkermes PLC common stock, representing 5.8% of the class. The filing shows sole dispositive power over 9,647,056 shares and sole voting power over 135,944 shares. The statement attributes holdings to Vanguard Portfolio Management LLC and affiliated divisions.
Alkermes PLC ownership disclosure: Vanguard Capital Management reports beneficial ownership of 8,676,888 shares of Alkermes common stock, representing 5.21% of the class as reported. The filing shows 1,249,491 shares with sole voting power and 8,676,888 shares with sole dispositive power. The disclosure is signed by Ashley Grim.
Alkermes plc. director Nancy Lurker reported a routine equity compensation event. She exercised a restricted stock unit award covering 3,751 ordinary shares, converting it into the same number of ordinary shares at a stated price of $0.00 per share.
Of these shares, 901 ordinary shares were withheld at $33.36 per share to cover tax obligations related to the vesting, leaving her with 13,555 ordinary shares held directly after the transactions. The restricted stock units vest in three equal annual installments beginning on April 11, 2025.
Alkermes plc. executive David Joseph Gaffin, EVP and Chief Legal Officer of Alkermes, Inc., reported an open-market sale of company ordinary shares. He sold 2,034 Ordinary Shares at an average price of $34.57 per share. After this transaction, he directly holds 233,592 Ordinary Shares, indicating the sale was a small portion of his overall position. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person.
Alkermes plc is soliciting proxies for its 2026 annual meeting on May 20 in Dublin, where shareholders will elect directors, cast advisory votes on executive pay and auditor ratification, and consider approval of the amended 2018 stock plan and renewed Irish share issuance and pre‑emption waivers.
The proxy highlights 2025 performance, including approximately $1.48 billion in revenue and about $1.2 billion in proprietary product net sales, plus GAAP net income of roughly $242 million and Adjusted EBITDA of $394 million. It notes the completed acquisition of Avadel Pharmaceuticals, advances in the orexin 2 pipeline, and strong growth in VIVITROL, LYBALVI and ARISTADA. The filing also details CEO Richard Pops’ planned July 2026 retirement, Blair Jackson’s appointment as next CEO, extensive board refreshment and independence, pay‑for‑performance incentive design, and expanded ESG and shareholder‑engagement initiatives.
Alkermes plc filed Form 144 disclosing proposed sales of Common Stock linked to equity awards. The notice lists vesting of 1,164 restricted stock units and 870 performance share units (awarded in 2017 and 2015). The filing shows two proposed transactions dated 03/02/2026 and 03/03/2026 with amounts 59,575.86 and 60,531.84.
Alkermes plc EVP R&D and Chief Medical Officer Craig C. Hopkinson exercised employee stock options for 5,000 Ordinary Shares at an exercise price of $19.34 per share and acquired the related shares. On the same date, he sold 9,000 Ordinary Shares at a weighted average price of $35.5116 per share in an open-market transaction.
Both the option exercise and the share sale were effected under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2025. After these transactions, Hopkinson directly held 85,389 Ordinary Shares. The options exercised were fully vested in accordance with their terms, and no remaining derivative positions are shown in this filing.
Alkermes plc: Craig Hopkinson reported multiple planned sales of Ordinary shares on Form 144, including transactions from 12/01/2025 through 03/02/2026. Recent reported sales include 9,000 shares on 02/02/2026 for $305,384.28 and 9,000 shares on 03/02/2026 for $267,485.14.
The filing also lists exercises and vesting events: a 5,000-share broker-assisted cashless exercise on 04/01/2026 and several performance share award vestings in 2025–2026. These entries are routine disclosures of secondary market sales and compensation-related issuances.
Alkermes plc is soliciting proxies for its 2026 Annual General Meeting of Shareholders to be held on May 20, 2026, subject to completion. The meeting will consider election of directors, advisory and ratification votes on executive compensation and auditor appointment, renewal of share-allotment and pre-emption authorities, and approval of the amended 2018 Stock Option and Incentive Plan.
Shareholders of record as of March 13, 2026 may vote. The filing highlights 2025 results including $1.48 billion total revenues, $1.2 billion proprietary product net sales, GAAP net income of $242 million, $394 million Adjusted EBITDA, and a year-over-year increase in cash and investments of approximately $495 million. The proxy statement discloses the CEO succession plan (CEO retirement effective July 31, 2026; successor effective August 1, 2026) and notes the completed acquisition of Avadel in February 2026.